China's biotech revival is pushing up prices of laboratory monkeys used in drug testing, as renewed R&D activity collides ...

Parabilis Medicines is taking an early lead in the 2026 biotech fundraising race, closing a $305 million series F round that ...

Bioprinting is rapidly moving from research labs into commercial reality, and it is reshaping how the pharmaceutical and ...

Noetik CEO and co-founder Ron Alfa, M.D., Ph.D., said the licensing of human foundation models is “a new paradigm in biotech.

According to Gartner, 58% of finance functions employed AI in 2024—a 21-percentage-point jump from the prior year. PwC ...

PharmAla Biotech Holdings Inc. ('PharmAla” or the 'Company”) (CSE: MDMA) (OTCQB:MDXXF), a biotechnology company focused on ...

Amgen has bought cancer biotech Dark Blue Therapeutics in a deal that could be worth as much as $840mn, marking the latest ...

As we head into the 2026, let's take a look at biotech licensing deals and M&As that were inked in December 2025.

ATLATL, one of China’s leading biotech incubators, is seeking to bridge East-West innovation and tap into China's rapidly ...

Danish biotech startup Bactolife has secured more than €30 million in a Series B funding round, marking a significant ...

The cost of the monkeys — a proxy for the volume of clinical trials — is projected to reach Rmb150,000 ($21,000) at the start ...